CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL

Chimeric antigen receptor (CAR) T-cells targeting CD19 mediate potent effects in relapsed/refractory pre-B cell acute lymphoblastic leukemia (B-ALL) but antigen loss is a frequent cause of resistance to CD19-targeted immunotherapy. CD22 is also expressed on most B-ALL and usually retained following...

Descripción completa

Detalles Bibliográficos
Autores principales: Fry, Terry J., Shah, Nirali N., Orentas, Rimas J., Stetler-Stevenson, Maryalice, Yuan, Constance M., Ramakrishna, Sneha, Wolters, Pamela, Martin, Staci, Delbrook, Cindy, Yates, Bonnie, Shalabi, Haneen, Fountaine, Thomas J., Shern, Jack F., Majzner, Robbie G., Stroncek, David F., Sabatino, Marianna, Feng, Yang, Dimitrov, Dimiter S., Zhang, Ling, Nguyen, Sang, Qin, Haiying, Dropulic, Boro, Lee, Daniel W., Mackall, Crystal L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774642/
https://www.ncbi.nlm.nih.gov/pubmed/29155426
http://dx.doi.org/10.1038/nm.4441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774642/
https://www.ncbi.nlm.nih.gov/pubmed/29155426
http://dx.doi.org/10.1038/nm.4441

Ejemplares similares